IN-VIVO PHARMACOKINETIC EVALUATION OF PIOGLITAZONE – HPMC K 15 M FLOATING TABLETSAbstract
The objective of the study is to make a pharmacokinetic evaluation of Pioglitazone floating tablets formulated employing HPMC K 15 M in comparison to Pioglitazone pure drug in rabbits. The two products were tested in a crossover RBD in healthy rabbits of either sex (n=6). The plasma concentrations of Pioglitazone were determined by a validated HPLC method. From the time versus plasma concentration data, various pharmacokinetic parameters (Cmax, Tmax, t1/2, AUC, Ka, and MRT) were calculated. Pioglitazone from the floating tablets formulated was absorbed slowly over longer periods in-vivo resulting in the maintenance of plasma concentrations within a narrow range over a longer period. The absorption rate constant (Ka) was decreased from 1.462 h-1 for Pioglitazone pure drug to 0.1598 h-1 with the floating tablets. MRT was increased from 9.82 h for Pioglitazone pure drug to 13.30 h with the floating tablets. There was no increase in the bioavailability of Pioglitazone from the floating tablets developed.
G. C. Devi
University College of Pharmaceutical Sciences, Palamuru University, Bandameedipally, Mahabub Nagar, Telangana, India.
26 July 2018
01 October 2018
03 October 2018
01 April 2019